Advanced Filters
noise
Found 1,889 clinical trials
X Xiaoyang Li, M.D.

Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. …

18 - 70 years of age All Phase 1/2
A ABEL HUANG

Non-small Cell Lung Cancer With Central Nervous System Metastasis

Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, …

20 - 90 years of age All Phase N/A

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Immunotherapy has recently become a main-stream treatment option in cancer care, with improved clinical outcomes in many malignancies, especially that of lung cancer. The long-term benefits of this treatment however are limited. There is therefore a critical need to distinguish predictive biomarkers of response from those of resistance, and to …

18 years of age All Phase 2
N Natasha Leighl

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective …

18 years of age All Phase 2

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: The 5-year disease-free …

18 - 80 years of age All Phase 3
C Chiara Bennati, MD

Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment

This is an interventional, non-pharmacologic, randomized controlled study evaluating the impact on quality of life of a personalized exercise program in oncogene addicted lung cancer patients undergoing active treatment. Patients will be randomized 1:1 in two arms: arm A (interventional) and arm B (control). The program of physical activity will …

18 years of age All Phase N/A
S Site Public Contact

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will …

18 years of age All Phase 2
L Line Sparvath

Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer

Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them …

18 years of age All Phase N/A

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Lung cancer is a highly prevalent disease worldwide in women and men. In 2022, lung cancer stood as the most frequently diagnosed cancer with approximately 2.48 million new cases on a global scale, followed by cancers of the female breast (11.6%), colorectum (9.6%), prostate (7.3%), and stomach (4.9%). Lung cancer …

18 - 130 years of age All Phase 3
X Xiaomin Niu

Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

Immunotherapy has improved the prognosis of non-small cell lung cancer (NSCLC) patients, but about 80% of patients do not respond at all (primary resistance), and some patients initially respond to immunotherapy, later relapse and develop disease progression (acquired resistance). So the objective of this research is to explore the sugar …

18 years of age All Phase N/A

Simplify language using AI